Lindbrook Capital, LLC Hutchmed (China) LTD Transaction History

Lindbrook Capital, LLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 Apr 21, 2022	SELL	$15.52 - $35.65 $9,467 - $21,746	-610 Closed	0 $0
Q4 2021 Jan 18, 2022	BUY	$28.89 - $35.33 $2,802 - $3,427	97 Added 18.91%	610 $21,000
Q2 2021 Jul 27, 2021	SELL	$23.7 - $39.27 $2,085 - $3,455	-88 Reduced 14.64%	513 $20,000
Q4 2020 Jan 27, 2021	BUY	$27.51 - $34.36 $137 - $171	5 Added 0.84%	601 $19,000
Q3 2020 Nov 03, 2020	BUY	$25.8 - $34.61 $438 - $588	17 Added 2.94%	596 $19,000
Q2 2020 Jul 27, 2020	BUY	$17.65 - $28.05 $3,141 - $4,992	178 Added 44.39%	579 $16,000
Q1 2020 Apr 22, 2020	BUY	$15.19 - $29.51 $6,091 - $11,833	401 New	401 $7,000

6.88M

6.2K

1.1K

Ticker HCM
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 172,955,008
Market Cap $2.47B
Description
HUTCHMED (China) Limited discovers, develops, and commercializes targeted therapeutics and immunotherapies for cancer and immunological diseases in HongKong and internationally. It operates in Oncology/Immunology and Other Ventures segments. The company develops Savolitinib, an inhibitor for non-small cell lung cancer (NSCLC), papillary and rena...

Get notified when there are updates to the investment portfolio of Lindbrook Capital, LLC, based on Form 13F filings with the SEC.

Stay updated on Lindbrook Capital, LLC with notifications on news.